These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34807258)

  • 1. Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.
    Lin SY; Baumann K; Zhou C; Zhou W; Cuellar AE; Xue H
    JAMA Netw Open; 2021 Nov; 4(11):e2135371. PubMed ID: 34807258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey.
    Salami JA; Warraich H; Valero-Elizondo J; Spatz ES; Desai NR; Rana JS; Virani SS; Blankstein R; Khera A; Blaha MJ; Blumenthal RS; Lloyd-Jones D; Nasir K
    JAMA Cardiol; 2017 Jan; 2(1):56-65. PubMed ID: 27842171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
    Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
    JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
    Yeung K; Dusetzina SB; Basu A
    JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of manufacturer coupon use in the statin market.
    Daugherty JB; Maciejewski ML; Farley JF
    J Manag Care Pharm; 2013; 19(9):765-72. PubMed ID: 24156645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encouraging generic use can yield significant savings.
    Zimmerman C
    Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
    Haas JS; Phillips KA; Gerstenberger EP; Seger AC
    Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Evergreened Reformulations on Medicaid Expenditures and Patient Access from 2008 to 2016.
    Dickson S
    J Manag Care Spec Pharm; 2019 Jul; 25(7):780-792. PubMed ID: 30799664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate.
    Rome BN; Tessema FA; Kesselheim AS
    JAMA Intern Med; 2020 Sep; 180(9):1165-1172. PubMed ID: 32897384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
    Cheng N; Banerjee T; Qian J; Hansen RA
    J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
    Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
    JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Use and Expenditures of Brand-name Atorvastatin After Introduction of Generic Atorvastatin.
    Warraich HJ; Salami JA; Khera R; Valero-Elizondo J; Okunrintemi V; Nasir K
    JAMA Intern Med; 2018 May; 178(5):719-721. PubMed ID: 29525818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF; Merrell K; Hargrave E; Summer L
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of prescription drug costs in the United States and the United Kingdom, Part 1: statins.
    Jick H; Wilson A; Wiggins P; Chamberlin DP
    Pharmacotherapy; 2012 Jan; 32(1):1-6. PubMed ID: 22392823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.